A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes

被引：0
|
作者：
Andreas Andersen
Filip Krag Knop
Tina Vilsbøll
机构：
[1] University of Copenhagen,Steno Diabetes Center Copenhagen, Gentofte Hospital
[2] University of Copenhagen,Center for Clinical Metabolic Research, Gentofte Hospital
[3] University of Copenhagen,Department of Clinical Medicine, Faculty of Health and Medical Sciences
[4] University of Copenhagen,Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences
来源：
Drugs | 2021年 / 81卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1003 / 1030
页数：27
相关论文
共 50 条
  • [31] Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
    Kane, Michael P.
    Triplitt, Curtis L.
    Solis-Herrera, Carolina D.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (07) : 556 - 567
  • [32] The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs
    Joshi, Shashank R.
    Rajput, Rajesh
    Chowdhury, Subhankar
    Singh, Awadhesh K.
    Bantwal, Ganapathi
    Das, Ashok K.
    Unnikrishnan, A. G.
    Saboo, Banshi D.
    Kesavadev, Jothydev
    Ghosal, Samit
    Mohan, Viswanathan
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2022, 16 (06)
  • [33] A RESPONSE TO: "COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES"
    Kohli-Lynch, Ciaran N.
    Ruiz-Negron, Natalia
    Beal, Amy
    Bellows, Brandon K.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (08): : 1140 - 1141
  • [34] Oral Semaglutide: A New GLP-1 Receptor Agonist Product for the Treatment of Type 2 Diabetes
    Smith, Connor K.
    Neumiller, Joshua J.
    US PHARMACIST, 2019, 44 (10) : 36 - 45
  • [35] Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
    Doggrell, Sheila A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (05) : 489 - 492
  • [36] Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment
    Baldassarre, Maria Pompea Antonia
    Di Dalmazi, Giulia
    Coluzzi, Sara
    Carrieri, Federica
    Febo, Fabrizio
    Centorame, Giorgia
    Cassino, Piergiuseppe
    Piacentino, Luigi
    Baroni, Marco Giorgio
    Consoli, Agostino
    Formoso, Gloria
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (11)
  • [37] Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo
    Lavernia, Frank
    Blonde, Lawrence
    POSTGRADUATE MEDICINE, 2020, 132 : 15 - 25
  • [38] Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide
    Swift, Caroline
    Frazer, Monica S.
    Gronroos, Noelle N.
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    Guevarra, Mico
    DIABETES THERAPY, 2024, 15 (07) : 1547 - 1559
  • [39] Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study
    Martinez-Montoro, Jose Ignacio
    Picon-Cesar, Maria Jose
    Generoso-Pinar, Marta
    Fernandez-Valero, Andrea
    Lopez-Montalban, Angel
    Simon-Frapolli, Victor Jose
    Hernandez-Bayo, Juan
    Pinzon-Martin, Jose Luis
    Tinahones, Francisco J.
    JOURNAL OF INTERNAL MEDICINE, 2024, 295 (01) : 113 - 115
  • [40] Reality of Real-World Experience with Oral Semaglutide in Type 2 Diabetes
    Singh, Awadhesh Kumar
    Singh, Akriti
    Singh, Ritu
    Swain, Jayshree
    CLINICAL DIABETOLOGY, 2024, 13 (06): : 319 - 322
12345